Home > Resources > Whitepapers > Live-Cell Analysis of Cell Subsets and Heterogeneity

Live-Cell Analysis of Cell Subsets and Heterogeneity

July 30, 2018

Considerable heterogeneity exists in the properties and activity of individual cells, even in the simplest cell system. Analysis at the cell-by-cell level promises valuable and additional biological insight beyond which whole population measures may deliver. In this article, we consider this opportunity from a perspective of analyzing living cells over time, and describe new, enabling and industrial-scale, live-cell analysis solutions for quantifying the phenotypic biology of cell subsets in heterogeneous cultures.

Spotlight

PatientFocus

PatientFocus is a medical billing company, that functions as an outsourced extension of our clients’ billing office. We focus exclusively on patient-pay billing – after insurance (or no insurance) and before bad debt – and facilitate patient communications, payment management, and patient financing options. The heart of the PatientFocus solution is the patient. Our unique combination of people, process and platform, and our “Day One” approach results in a highly coordinated, more comprehensive, and extremely efficient outreach program that protects both the patients’ experience and our clients’ brand.

OTHER WHITEPAPERS

Are Nitrosamines aConcern for BiologicManufacturers?

whitePaper | July 12, 2023

The discovery of nitrosamine genotoxins in several pharmaceuticals has led to monitoring and re-evaluation of manufacturing practices for those products considered atrisk. This article provides an assessment of nitrosamine contamination specifically in biologics and contrasts the potential risks between these product types.

Characterization and identification of glucuronide metabolites

whitePaper | April 21, 2023

This technical note demonstrates the comprehensive characterization and confident identification of glucuronide metabolites from hepatocyte incubations of midazolam. An orthogonal fragmentation mechanism was applied to generate diagnostic fragmentions for confident identification of glucuronide metabolites

Early engagement and regulatory considerations for biotech

whitePaper | March 24, 2023

Biotechnology companies are at the epicenter of innovative drug development, with discoveries spanning from small molecules, large molecules, and biologics to genomic medicines and first-inclass immunotherapies.

Antibodies to Viral Vectors Responding to Demands toSimplify Progress in Bioprocessing

whitePaper | March 16, 2023

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

State of the Global Biotech Landscape: Where the Opportunities Lie

whitePaper | December 13, 2022

Over the last five years, the global biotech and pharmaceutical landscape has witnessed continued growth. The analysis period (2017-2022) encompasses a unique timeframe including the global COVID-19 pandemic.

A Cornerstone in the Supply Chain of Cell-based Therapies

whitePaper | February 15, 2023

The diverse therapeutic attributes of mesenchymal stromal cells (MSCs) lend to their rapid development as cellular therapeutics. These unique attributes include potent immu nomodulatory properties [1,2], the potential to differentiate into multiple cell lineages.